

# Siegfried DINAMIQS receives Swissmedic license for viral vector manufacturing

## Media Release

Zofingen  
April 29, 2026

- DINAMIQS receives Swissmedic license for viral vector manufacturing and testing under cGMP
- Approval enables cGMP-compliant production and release of genomic medicines, supporting global customer programs and regulatory pathways
- With this license, Siegfried strengthens its position in the fast-growing cell and gene therapy market

DINAMIQS, a Siegfried company (SIX: SFZN) today announced that it has received a manufacturing and testing license from Swissmedic for viral vector cGMP production. With this approval, DINAMIQS is authorized to manufacture and release genomic medicines under GMP conditions, marking an important milestone in expanding Siegfried's capabilities in advanced therapies and strengthening its offering to global customers.

The license positions DINAMIQS as a fully integrated viral vector CDMO providing end-to-end services from process development to drug product manufacturing.

**Marcel Imwinkelried, CEO Siegfried:** "The Swissmedic approval is a key step in scaling DINAMIQS into a leading viral vector CDMO. It strengthens our strategic position in advanced therapies and underlines our ambition to provide fully integrated, high-quality solutions to customers worldwide."

**Martin Kessler, CEO DINAMIQS:** "Obtaining the license is an important milestone on our journey. Our customers don't just get GMP manufacturing – they get speed, reliability, and a clear path towards approval. We take complexity out of their way and help bring programs faster to clinic and market."

Located in Zurich, the 2,500 m<sup>2</sup> cGMP facility is purpose-built for viral vector manufacturing at scales of up to 1,000L. It integrates process development, drug substance production, aseptic fill-finish, and quality control testing in one place, helping reduce complexity, timelines, and technology transfer risks for customers. Designed in accordance with EU GMP Annex 1, the facility ensures full regulatory compliance for global market supply. DINAMIQS has successfully produced more than 300 batches of Adeno-Associated and Lentiviral vectors, with the first batch from the new facility achieving best-in-class results in yield and quality.

Swissmedic is internationally recognized for its high quality and compliance standards. Switzerland's mutual recognition agreements with the European Medicines Agency and the U.S. Food and Drug Administration support efficient regulatory pathways, facilitating broader market access for products manufactured under Swissmedic oversight.

With the Swissmedic license in place, DINAMIQS is well positioned to partner with gene therapy innovators worldwide, supporting the development and commercialization of next-generation therapies.

**Contact Media**

Peter Stierli  
Head Corporate Communications  
peter.stierli@siegfried.ch  
+41 62 746 15 51

**Contact Financial Analysts**

Dr. Reto Suter  
Chief Financial Officer  
reto.suter@siegfried.ch  
+41 62 746 11 35

Siegfried Holding AG,  
Untere Bruehlstrasse 4  
CH-4800 Zofingen

[www.siegfried.ch](http://www.siegfried.ch)

**About Siegfried**

The Siegfried Group is a contract development and manufacturing company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2025, the company achieved sales of CHF 1,327.8 million and employed on 31.12.2025 more than 3,800 people at thirteen sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services.

**About DINAMIQS**

DINAMIQS, a Siegfried company, is a science-driven Contract Development and Manufacturing Organization (CDMO) offering end-to-end viral vector development and manufacturing solutions. DINAMIQS offers a comprehensive and customized range of manufacturing services, process development, quality control and analytics solutions for genetic medicine companies.

DINAMIQS partners with both large and emerging biopharma customers. The company is located in the Bio-Technopark in Schlieren, Zurich, Switzerland.

**Cautionary Statements Regarding Forward-Looking Statements**

This media release includes statements concerning the future. They are based on assumptions and expectations that may prove to be wrong. They should be considered with due caution as, by definition, they contain known and unknown risks, insecurities and other factors which could result in a difference in the actual results, financial situation, developments or the success of Siegfried Holding AG or Siegfried Group from the explicit or implicit assumptions made in these statements.